Z-BEAM PHOTON THERAPY

FOR THE PREVENTION AND RELIEF OF ORAL MUCOSITIS

About CuraLase

CuraLase clinics has administered over 100,000 treatments to over 8,000 patients from 44 states and 31 countries, establishing an international reputation for exceptional patient care. Achieving over a 90% success rate, CuraLase offers a non-invasive treatment option to individuals with pain. CuraLase delivers a pathway for patients to “get their quality of life back.”

PATIENTS

TREATMENTS

SUCCESS

Why CuraLase?

The CuraLase crystal controlled frequency Photon Therapy technology produces a monochromatic, coherent beam, which delivers the most pure, powerful, fastest and deepest penetrating source of energy to the cells. This separates and distinguishes CuraLase from all the diode and LED devices on today’s market.

Years of laboratory and clinical research data have established that one of the most important variables in the delivery of (photon therapy, PBM therapy) is wavelength. Delivery of photon energy must be via a wavelength that not only stimulates the cellular processes, but also is able to penetrate into deeper tissues without being absorbed by tissues superficial to the intended target. Curalase delivers this appropriate wavelength, and delivers it with a consistency of +/- 0.5 nm variation. This is unique to the CuraLase Z-Beam Photon Therapy technology.

The CuraLase History

Since its founding in 2005, CuraLase has been an innovator in non-invasive Photon Therapy treatment for a multitude of painful conditions. Roger Porter, inventor and engineer, was seeking an alternative treatment for a family member’s excruciating pain from rheumatoid arthritis when he met Frank G. McArthur, MD. Dr. McArthur was the Medical Director of the largest chain of rehab hospitals in the World (Health South). Working together, Porter and McArthur researched and developed an innovative device and initial protocols. In December 2005, the CuraLase device was FDA cleared for its use and sales. The FDA rated the CL1000 with the safest classification awarded to any treatment modality – Non-Significant Risk. The first clinic opened in March 2006 in Myrtle Beach, South Carolina. Porter and a team of seven physicians refined the initial treatment protocols and developed new treatment protocols with great success.

PHOTON THERAPY

Photon therapy is (essentially) the delivery of discrete packets of energy to the deep tissue. The effectiveness of photon therapy is entirely contingent upon the existence of chromophores, intracellular molecular substrates that are capable of responding to this light stimulation.

This is not entirely unlike the effect of sunlight on chlorophyll molecules. Just as is the case with Photon Therapy, sunlight would have no impact on any plant cellular processes without specific molecular substrates that are sensitive to the sunlight. The research into photon therapy has been focused on establishing the fact that there are light sensitive molecular substrates widely distributed within tissue, that it is possible to design a mechanism for delivering the specific wavelength to which these substrates will respond, and most important, the stimulation of these substrates results in cellular activation positively impacting a wide scope of therapeutic outcomes.

For over a decade the developers of CuraLase have been refining this photon delivery method, and have developed a device that provides wavelength that not only is matched specifically to the receptors at the cellular level, but is also avoids absorption by water, fat and other soft tissue during the delivery process.

CuraLase was awarded FDA clearance in 2005.

CuraLase Medical Advisory Board

John Charles, MD

Emergency Medicine Specialist

LINK TO BIO & VIDEO
Praveen Arany, DDS, PHD

University of Buffalo School of Medicine

LINK TO BIO & VIDEO

CLINICAL TRIALS

PHOTON THERAPY
“HARVARD CLINICAL TRIAL PROVES PHOTON THERAPY ACTIVATE STEM CELLS TO REGENERATE TISSUE”

Study Location:
Harvard School of Engineering and Applied Sciences (SEAS)
Author Information:
David J. Mooney, Praveen Arany, Ph.D., 

CONCLUSION:
Harvard’s groundbreaking new research in the use of Photon Therapy to stimulate stem cells to regrow tissue is generating interest and excitement throughout the medical community.

https://www.seas.harvard.edu/news/2014/05/researchers-use-light-to-coax-stem-cells-to-repair-teeth
“The mechanistic basis for Photon Therapy of neuropathic pain”

Study Location:
Center of Neurology and Neurosurgery Associates, Beneficência of São Paulo Hospital, São Paulo, Brazil
Author Information:
Holanda VM, Chavantes MC, Wu X, Anders.

CONCLUSION:
These in vitro and in vivo studies indicate that treatment with Photon Therapy can rapidly block pain transmission.

https://www.ncbi.nlm.nih.gov/pubmed/28075022
“Photon Therapy following acute hepatectomy most probably stimulates a significant enhancement of liver regeneration”

Study Location:
Department of Zoology, Life Sciences Faculty, Tel-Aviv University, Tel-Aviv, Israel
Author Information:
Oron U, Maltz L, Tuby H, Sorin V, Czerniak A.

CONCLUSION:
It is concluded that Photon Therapy, following acute hepatectomy,  stimulates a significant enhancement of liver regeneration conducive to both the formation of new hepatocytes and MSCs and angiogenesis in the regenerating liver.

http://www.ncbi.nlm.nih.gov/pubmed/20932182
“Photon Therapy of the dorsal root ganglion for the treatment of low back pain.”

Study Location:
Post Graduate Program in Biophotonics Applied to Health Sciences and in Medicine, University Nove de Julho-UNINOVE, São Paulo, Brazil.
Author Information:
Holanda VM, Chavantes MC, Silva DF, de Holanda CV, de Oliveira JO Jr, Wu X, Anders JJ.

CONCLUSION:
Photon Therapy irradiation caused an immediate decrease in low back pain post-procedure similar to pain reduction caused by lidocaine injection.

https://www.ncbi.nlm.nih.gov/pubmed/27135465

Contact CuraLase

info@curalase.com

+1-843-716-5300